Resolution Bioscience is Now Part of Agilent

On April 15, 2021, Agilent completed the acquisition of Resolution Bioscience, a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing precision medicine market.

Below are answers to common questions about Resolution Bioscience and Agilent.

Q: Who do I contact to inquire about Resolution Bioscience solutions?

As the process for integrating Resolution Bioscience into Agilent continues, all inquiries for Resolution Bioscience will be processed directly through Resolution Bioscience, just as they were prior to the company’s acquisition by Agilent. For assistance, please contact Resolution Bioscience directly.

Q: Who do I contact to inquire about Resolution Bioscience solutions?

As the process for integrating Resolution Bioscience into Agilent continues, all inquiries for Resolution Bioscience will be processed directly through Resolution Bioscience, just as they were prior to the company’s acquisition by Agilent. For assistance, please contact Resolution Bioscience directly.

Q: I recently purchased a solution from Resolution Bioscience, how will the merger affect me?

Resolution Bioscience will continue to be your direct contact as the integration progresses. Please continue to contact the same personnel that you did prior to the acquisition.

Q: Can Agilent customers include Resolution Bioscience solutions in their Agilent orders?

For now, all orders for Resolution Bioscience solutions must be handled through Resolution Bioscience. We will update this information at the appropriate time, as the integration of Agilent and Resolution Bioscience continues.